91 related articles for article (PubMed ID: 15032076)
1. Immunohistochemical evaluation of urokinase plasminogen activator receptor in noninvasive and early invasive urothelial papillary neoplasia.
Vivani C; Magi S; Mazzucchelli R; Bacchiocchi R; Santinelli A; Muzzonigro G; Blasi F; Montironi R; Fazioli F
Anal Quant Cytol Histol; 2004 Feb; 26(1):15-21. PubMed ID: 15032076
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
3. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
4. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
6. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
7. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
[TBL] [Abstract][Full Text] [Related]
8. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder.
Alrashidy M; Atef A; Baky TA
Asian Pac J Cancer Prev; 2016; 17(4):1769-72. PubMed ID: 27221850
[TBL] [Abstract][Full Text] [Related]
10. High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.
Džombeta T; Krušlin B
Pathol Oncol Res; 2018 Jul; 24(3):567-574. PubMed ID: 28752222
[TBL] [Abstract][Full Text] [Related]
11. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
13. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Lindberg P; Larsson A; Nielsen BS
Int J Cancer; 2006 Jun; 118(12):2948-56. PubMed ID: 16395714
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
15. uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Dohn LH; Pappot H; Iversen BR; Illemann M; Høyer-Hansen G; Christensen IJ; Thind P; Salling L; von der Maase H; Laerum OD
PLoS One; 2015; 10(8):e0135824. PubMed ID: 26292086
[TBL] [Abstract][Full Text] [Related]
16. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F
BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma.
El-Kott AF; Khalil AM; El-Kenawy Ael-M
Int Urol Nephrol; 2004; 36(3):417-23. PubMed ID: 15783118
[TBL] [Abstract][Full Text] [Related]
19. Expression of maspin in papillary Ta/T1 bladder neoplasms.
Blandamura S; D'Alessandro E; Giacomelli L; Guzzardo V; Battanello W; Repele M; Ninfo V
Anticancer Res; 2008; 28(1B):471-8. PubMed ID: 18383887
[TBL] [Abstract][Full Text] [Related]
20. Histopathological and immunohistochemical study of papillary urothelial neoplasms of low malignant potential and grade associated with extensive invasive low-grade urothelial carcinoma.
Mai KT; Elmontaser G; Perkins DG; Yazdi HM; Stinson WA; Thijssen A
BJU Int; 2004 Sep; 94(4):544-7. PubMed ID: 15329109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]